Cargando…

mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects

To identify the most efficient methods of immunological protection against SARS-CoV-2, including the currently most widespread variants of concern (VOCs)—B.1.1.7, B.1.351 and P.1—a simultaneous side-by-side-comparison of available vaccination regimes is required. In this observational cohort study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabricius, Dorit, Ludwig, Carolin, Scholz, Judith, Rode, Immanuel, Tsamadou, Chrysanthi, Jacobsen, Eva-Maria, Winkelmann, Martina, Grempels, Aline, Lotfi, Ramin, Janda, Aleš, Körper, Sixten, Adler, Guido, Debatin, Klaus-Michael, Schrezenmeier, Hubert, Jahrsdörfer, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402682/
https://www.ncbi.nlm.nih.gov/pubmed/34452043
http://dx.doi.org/10.3390/vaccines9080918
_version_ 1783745849583468544
author Fabricius, Dorit
Ludwig, Carolin
Scholz, Judith
Rode, Immanuel
Tsamadou, Chrysanthi
Jacobsen, Eva-Maria
Winkelmann, Martina
Grempels, Aline
Lotfi, Ramin
Janda, Aleš
Körper, Sixten
Adler, Guido
Debatin, Klaus-Michael
Schrezenmeier, Hubert
Jahrsdörfer, Bernd
author_facet Fabricius, Dorit
Ludwig, Carolin
Scholz, Judith
Rode, Immanuel
Tsamadou, Chrysanthi
Jacobsen, Eva-Maria
Winkelmann, Martina
Grempels, Aline
Lotfi, Ramin
Janda, Aleš
Körper, Sixten
Adler, Guido
Debatin, Klaus-Michael
Schrezenmeier, Hubert
Jahrsdörfer, Bernd
author_sort Fabricius, Dorit
collection PubMed
description To identify the most efficient methods of immunological protection against SARS-CoV-2, including the currently most widespread variants of concern (VOCs)—B.1.1.7, B.1.351 and P.1—a simultaneous side-by-side-comparison of available vaccination regimes is required. In this observational cohort study, we compared immunological responses in 144 individuals vaccinated with the mRNA vaccines BNT162b2 or mRNA-1273 and the vector vaccine ChAdOx1-nCoV-19, either alone, in combination, or in the context of COVID-19-convalescence. Unvaccinated COVID-19-convalescent subjects served as a reference. We found that cellular and serological immune responses, including neutralizing capacity against VOCs, were significantly stronger with mRNA vaccines as compared with COVID-19-convalescent individuals or vaccinated individuals receiving the vector vaccine ChAdOx1-nCoV-19. Booster immunizations with mRNA vaccines triggered strong and broadly neutralizing antibody and IFN-γ responses in 100% of vaccinated individuals investigated. This effect was particularly strong in COVID-19-convalescent and ChAdOx1-nCoV-19-primed individuals, who were characterized by comparably moderate cellular and neutralizing antibody responses before mRNA vaccine booster. Heterologous vaccination regimes and convalescent booster regimes using mRNA vaccines may allow enhanced protection against SARS-CoV-2, including current VOCs. Furthermore, such regimes may facilitate rapid (re-)qualification of convalescent plasma donors with high titers of broadly neutralizing antibodies.
format Online
Article
Text
id pubmed-8402682
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84026822021-08-29 mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects Fabricius, Dorit Ludwig, Carolin Scholz, Judith Rode, Immanuel Tsamadou, Chrysanthi Jacobsen, Eva-Maria Winkelmann, Martina Grempels, Aline Lotfi, Ramin Janda, Aleš Körper, Sixten Adler, Guido Debatin, Klaus-Michael Schrezenmeier, Hubert Jahrsdörfer, Bernd Vaccines (Basel) Article To identify the most efficient methods of immunological protection against SARS-CoV-2, including the currently most widespread variants of concern (VOCs)—B.1.1.7, B.1.351 and P.1—a simultaneous side-by-side-comparison of available vaccination regimes is required. In this observational cohort study, we compared immunological responses in 144 individuals vaccinated with the mRNA vaccines BNT162b2 or mRNA-1273 and the vector vaccine ChAdOx1-nCoV-19, either alone, in combination, or in the context of COVID-19-convalescence. Unvaccinated COVID-19-convalescent subjects served as a reference. We found that cellular and serological immune responses, including neutralizing capacity against VOCs, were significantly stronger with mRNA vaccines as compared with COVID-19-convalescent individuals or vaccinated individuals receiving the vector vaccine ChAdOx1-nCoV-19. Booster immunizations with mRNA vaccines triggered strong and broadly neutralizing antibody and IFN-γ responses in 100% of vaccinated individuals investigated. This effect was particularly strong in COVID-19-convalescent and ChAdOx1-nCoV-19-primed individuals, who were characterized by comparably moderate cellular and neutralizing antibody responses before mRNA vaccine booster. Heterologous vaccination regimes and convalescent booster regimes using mRNA vaccines may allow enhanced protection against SARS-CoV-2, including current VOCs. Furthermore, such regimes may facilitate rapid (re-)qualification of convalescent plasma donors with high titers of broadly neutralizing antibodies. MDPI 2021-08-18 /pmc/articles/PMC8402682/ /pubmed/34452043 http://dx.doi.org/10.3390/vaccines9080918 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fabricius, Dorit
Ludwig, Carolin
Scholz, Judith
Rode, Immanuel
Tsamadou, Chrysanthi
Jacobsen, Eva-Maria
Winkelmann, Martina
Grempels, Aline
Lotfi, Ramin
Janda, Aleš
Körper, Sixten
Adler, Guido
Debatin, Klaus-Michael
Schrezenmeier, Hubert
Jahrsdörfer, Bernd
mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects
title mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects
title_full mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects
title_fullStr mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects
title_full_unstemmed mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects
title_short mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects
title_sort mrna vaccines enhance neutralizing immunity against sars-cov-2 variants in convalescent and chadox1-primed subjects
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402682/
https://www.ncbi.nlm.nih.gov/pubmed/34452043
http://dx.doi.org/10.3390/vaccines9080918
work_keys_str_mv AT fabriciusdorit mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT ludwigcarolin mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT scholzjudith mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT rodeimmanuel mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT tsamadouchrysanthi mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT jacobsenevamaria mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT winkelmannmartina mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT grempelsaline mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT lotfiramin mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT jandaales mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT korpersixten mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT adlerguido mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT debatinklausmichael mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT schrezenmeierhubert mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects
AT jahrsdorferbernd mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects